SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE...
Transcript of SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE...
![Page 1: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/1.jpg)
SUBSTRATE REDUCTION THERAPY
for LYSOSOMAL STORAGE DISORDERS
Maria Francisca Coutinho*, Juliana Inês Santos*, Paulo Gaspar
and Sandra Alves
Lysosomal Storage Disorders Group
Research & Development Unit,
Department of Human Genetics,
INSA
14th International Symposium
15th-17th March, 2018
![Page 2: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/2.jpg)
LYSOSOMAL STORAGE DISORDERS
Genetic
Rare
Autosomal recessive (majority)
Portugal - 1/4000
Almost 60!
![Page 3: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/3.jpg)
LYSOSOMAL STORAGE DISORDERS (LSDS)
Chronic
Progressive
Large spectrum of severity
& symptoms
(from in utero/paediatric
to late adult onset forms)
Pathophysiology
still unknown!
![Page 4: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/4.jpg)
LYSOSOMAL STORAGE DISORDERS (LSDS)
![Page 5: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/5.jpg)
Progressive accumulation
DISEASE
LYSOSOMAL STORAGE DISORDERS (LSDS)
![Page 6: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/6.jpg)
1969
Elizabeth Neufeld
THE ENZYME AS A DRUG?
![Page 7: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/7.jpg)
trans
face
clathrin coat
transport vesicle
Late Endosome/
Lysosome
plasma membrane
THE ENZYME AS A DRUG?
![Page 8: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/8.jpg)
trans
face
clathrin coat
transport vesicle
Late Endosome/
Lysosome
plasma membrane
THE ENZYME AS A DRUG?
CI-MPR
clathrin-mediated
endocytosis
![Page 9: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/9.jpg)
PROOF OF PRINCIPLE…
Gaucher Disease (GD)
Deficient enzyme: -glucocerebrosidase
Gene: GBA (1q21)
Most frequent LSD
Original illustration by Marcos Bernardino for
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
![Page 10: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/10.jpg)
PROOF OF PRINCIPLE…
Gaucher Disease (GD)
Deficient enzyme: -glucocerebrosidase
Gene: GBA (1q21)
Intravenous injections of the
recombinant enzyme
Excellent results in systemic
disease
Original illustration by Marcos Bernardino for
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
![Page 11: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/11.jpg)
THE ENZYME AS A DRUG?
Pathology Available ERT
Gaucher Cerezyme® VPRIV® Elelyso®
(Imiglucerase; Genzyme) (Velaglucerase alfa; Shire) (Taliglucerase alfa; Pfizer)
Fabry Replagal® Fabrazyme®
(Agalsidase alfa; Shire) (Algalsidase beta; Genzyme)
MPS I Aldurazyme®
(Laronidase; Genzyme)
MPS II Elaprase®
(Idursulfase; Shire)
MPS IV A Vimizim®
(Elosulfase alfa; Biomarin)
MPS VI Naglazyme®
(Galsulfase; Biomarin)
Pompe Myozyme®
(Lumizyme, Alglucosidase alfa; Genzyme)
LAL
deficiency
Kanuma®
(Sebelipase alfa; Alexion)
![Page 12: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/12.jpg)
enzyme replacement
THE ENZYME AS A DRUG?
?
![Page 13: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/13.jpg)
1996
Norman Radin
THE ENZYME AS A DRUG?
![Page 14: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/14.jpg)
substrate reduction enzyme replacement
![Page 15: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/15.jpg)
SUBSTRATE REDUCTION THERAPY (SRT)
![Page 16: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/16.jpg)
SUBSTRATE REDUCTION THERAPY (SRT)
Pathology Approved SRT
Gaucher Zavesca®
(Miglustat; Actelion)
Cerdelga®
(Eliglustat tartrate; Genzyme)
Niemann-Pick C Zavesca®
(Miglustat; Actelion)
![Page 17: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/17.jpg)
SUBSTRATE REDUCTION THERAPY (SRT)
![Page 18: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/18.jpg)
GaucherFabry
Niemann-Pick
type CPompe
Mucopolysaccharidosis
type I
Sialidosis
Galactosialidosis
MPS IIIA
MPS II
MPS IIIB
MPS IIIC
Krabbe
Mucolipidosis
type II
Tay–Sachs
Metachromatic
leukodystrophy
Multiple sulfatase
deficiencyML III
Farber
SandhoffMPS IVA
MPS IVB
Fucosidosis
Alpha-
mannosidosis
Beta-mannosidosisPycnodysostosis
Danon
Wolman
![Page 19: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/19.jpg)
Chronic
Progressive
Large spectrum of severity
& symptoms
MUCOPOLYSACCHARIDOSES (MPS)
![Page 20: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/20.jpg)
Chronic
Progressive
Large spectrum of severity
& symptoms
MPS III
(= Sanfilippo Syndrome)
MUCOPOLYSACCHARIDOSES (MPS)
![Page 21: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/21.jpg)
MUCOPOLYSACCHARIDOSIS (MPS) TYPE III
Autosomal recessive
Lysosomal Storage Disorders
Sub-type of MPSs;
glycosaminoglycans (GAGs)
Accumulated substrate: heparan sulphate
4 different diseases:
III A
III B
III C
III D
depending on the defective enzyme
![Page 22: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/22.jpg)
AVAILABLE THERAPIES
None!
…only symptomatic!
ameliorate symptoms
support disabled patients
ERT for neurodegenerative MPS would require the
introduction of active enzyme into the CNS
extra difficulties!
![Page 23: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/23.jpg)
AVAILABLE THERAPIES
None!
…only symptomatic!
ameliorate symptoms
support disabled patients
ERT for neurodegenerative MPS would require the
introduction of active enzyme into the CNS
Still, it’s being attempted with
some promissing results
![Page 24: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/24.jpg)
AVAILABLE THERAPIES
None!
…only symptomatic!
ameliorate symptoms
support disabled patients
ERT for neurodegenerative MPS would require the
introduction of active enzyme into the CNS
Still, it’s being attempted with
some promissing results
Perfect Target
for
Substrate Reduction
Approaches!
![Page 25: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/25.jpg)
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
substrate reduction genetic
![Page 26: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/26.jpg)
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
early stage of the
HS biosynthetic cascade
![Page 27: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/27.jpg)
naturally occurring
post-transcriptional
gene silencing process
Designed to induce RNAi
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts
siRNAs
RISC
![Page 28: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/28.jpg)
Control fibroblasts
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
24/48h incubation
harvest cells
RNA extraction
cDNA synthesis
qRT-PCR (target gene expression assessment)
Livak method
NT
![Page 29: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/29.jpg)
mRNA
MPS III A MPS III C MPS III D
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts
![Page 30: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/30.jpg)
GAGs
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts
![Page 31: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/31.jpg)
GAGs
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts
Further validation:
nr of experiments;
immunocytochemistry
(anti-HS antibody)
+ tests in MPS IIIB
![Page 32: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/32.jpg)
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts
Promising results!
Reasons to keep studying...
![Page 33: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/33.jpg)
A LOOK FORWARD…
Vector design & siRNA encapsulation into liposomes
bioavailability of siRNAs;
protection from degradation
control of
circulation time
release rate
Coupling of specific ligands to
siRNA-carrying liposomes
o Transferrin (Tf)
o Rabies virus peptide derivative (RGV-2r)
Efficiency assessment
+ Targeting of brain cells
![Page 34: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/34.jpg)
A LOOK FORWARD…
in vivo
studies
![Page 35: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/35.jpg)
SUMMARY
“early stages” GAGs
biosynthesis gene
GAG storage
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
![Page 36: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/36.jpg)
SUMMARY
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
“early stages” GAGs
biosynthesis gene
Therapeutic use
![Page 37: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/37.jpg)
SUMMARY
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
“early stages” GAGs
biosynthesis gene
Holds potential to benefit
virtually all MPS!
![Page 38: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/38.jpg)
ACKNOWLEDGMENTS
Dr. Sandra Alves
Prof. Mª João Prata
Juliana Inês Santos
Paulo Gaspar
SFRH/BPD/101965/2014
SFRH/BD/124372/2016
bcp/LIM/DGH/Dz2015
António Reis
![Page 39: SUBSTRATE REDU N T APY L STORAGErepositorio.insa.pt/bitstream/10400.18/6287/3/Less...SUBSTRATE REDUCTION THERAPY for LYSOSOMAL STORAGE DISORDERS Maria Francisca Coutinho*, Juliana](https://reader033.fdocuments.in/reader033/viewer/2022050519/5fa30817daaba332421e042b/html5/thumbnails/39.jpg)
THANK YOU!